Celldex Therapeutics, Inc. (CLDX) stock is up 652.34% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives CLDX stock a score of 72 out of a possible 100.
That rank is mainly influenced by a long-term technical score of 90. CLDX's rank also includes a short-term technical score of 67. The fundamental score for CLDX is 59. In addition to the average rating from Wall Street analysts, CLDX stock has a mean target price of 26.333. This means analysts expect the stock to rise 36.72% over the next 12 months.
What's Happening with CLDX Stock Today
Celldex Therapeutics, Inc. (CLDX) stock has fallen -2.73% while the S&P 500 is up 0.68% as of 11:40 AM on Friday, Dec 4. CLDX is down -$0.54 from the previous closing price of $19.80 on volume of 176,937 shares. Over the past year the S&P 500 has gained 18.42% while CLDX is up 652.34%. CLDX lost -$2.22 per share in the over the last 12 months.